Abstract:Vaginitis, a prevalent gynecological condition in women, is mainly caused by an imbalance in the vaginal micro-ecology. The two most common types of vaginitis are vaginal bacteriosis and vulvovaginal candidiasis, triggered by the virulent Gardnerella vaginalis and Candida albicans , respectively. In this study, a strain capable of inhibiting G. vaginalis and C. albicans was screened from vaginal secretions and identified as Lactobacillus gasseri based on 16S rRNA sequences. The strain, named L. gasseri VHProbi E09, could inhibit the growth of G. vaginalis and C. albicans under co-culture conditions by 99.07% ± 0.26% and 99.95% ± 0.01%, respectively. In addition, it could significantly inhibit the adhesion of these pathogens to vaginal epithelial cells. The strain further showed the ability to inhibit the enteropathogenic bacteria Escherichia coli and Salmonella enteritidis , to tolerate artificial gastric and intestinal fluids and to adhere to intestinal Caco-2 cells. These results suggest that L. gasseri VHProbi E09 holds promise for clinical trials and animal studies whether administered orally or directly into the vagina. Whole-genome analysis also revealed a genome consisting of 1752 genes for L. gasseri VHProbi E09, with subsequent analyses identifying seven genes related to adhesion and three genes related to bacteriocins. These adhesion- and bacteriocin-related genes provide a theoretical basis for understanding the mechanism of bacterial inhibition of the strain. The research conducted in this study suggests that L. gasseri VHProbi E09 may be considered as a potential probiotic, and further research can delve deeper into its efficacy as an agent which can restore a healthy vaginal ecosystem.

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve This paper aims to address the common gynecological issue of vaginitis in women. Vaginitis is primarily caused by an imbalance in the vaginal microecology, with the two most common types being bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), caused by the pathogens *Gardnerella vaginalis* and *Candida albicans*, respectively. Currently, clinical strategies for treating these diseases mainly involve the use of antibiotics and antifungal drugs, but these treatments often lead to recurrence, necessitating the search for safe and effective alternative therapies. To tackle this challenge, researchers screened vaginal secretions and identified a lactic acid bacterium capable of inhibiting both *G. vaginalis* and *C. albicans*, which was identified as *Lactobacillus gasseri*. This strain was named *L. gasseri VHProbi E09* and demonstrated strong inhibitory effects against these two pathogens in vitro. Additionally, the strain showed inhibitory capabilities against intestinal pathogens *Escherichia coli* and *Salmonella enteritidis*, as well as tolerance to artificial gastric and intestinal fluids, and strong adhesion to vaginal epithelial cells and intestinal cells. These results suggest that *L. gasseri VHProbi E09* has the potential to be used as a probiotic in clinical trials and animal studies, either orally or directly applied to the vagina, to help restore a healthy vaginal ecosystem. ### Summary The main objective of this study is to screen and identify a lactic acid bacterium strain that can effectively inhibit vaginal pathogens, with the aim of developing new probiotic therapies to reduce the recurrence rate of vaginitis and improve women's quality of life. The in vitro experiments validated the antibacterial, antifungal, and adhesion capabilities of *L. gasseri VHProbi E09*, providing a theoretical basis for its further clinical application.

Characterization of a Lactobacillus gasseri strain as a probiotic for female vaginitis